Effect of Hemodialysis on Hepatic Cytochrome P450 Functional Expression
Cytochrome P450 (CYP) functional expression is reduced in uremia and normalized after restoration of kidney function via transplantation. The aim of this study was to evaluate the effect of conventional hemodialysis on the functional expression of CYP1A, 2C, and 3A. We also investigated the role of...
Saved in:
Published in | Journal of Pharmacological Sciences Vol. 108; no. 2; pp. 157 - 163 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Japan
Elsevier B.V
2008
The Japanese Pharmacological Society Elsevier |
Subjects | |
Online Access | Get full text |
ISSN | 1347-8613 1347-8648 |
DOI | 10.1254/jphs.08042FP |
Cover
Abstract | Cytochrome P450 (CYP) functional expression is reduced in uremia and normalized after restoration of kidney function via transplantation. The aim of this study was to evaluate the effect of conventional hemodialysis on the functional expression of CYP1A, 2C, and 3A. We also investigated the role of nuclear factor-κB (NF-κB) in CYP regulation during uremia. Primary cultures of normal rat hepatocytes were incubated with serum obtained from end-stage renal disease patients pre- and post-hemodialysis and healthy control subjects, in the presence and absence of the NF-κB inhibitor andrographolide. Uremic pre-hemodialysis serum caused significant reductions (P<0.01) in CYP1A (44%), 2C (27%), and 3A (35%) protein expression compared to control serum, while dialyzed serum (i.e., obtained immediately post-hemodialysis) had no effect. CYP1A2, 2C11, and 3A2 mRNA expression, as well as CYP3A activity, were similarly impacted by uremic serum and were improved to >80% of control values after hemodialysis. NF-κB inhibition nearly eliminated the effect of uremic serum on CYP functional expression. This is the first study to demonstrate that conventional hemodialysis acutely improves altered CYP functional expression observed in rat hepatocytes incubated with uremic human serum. |
---|---|
AbstractList | Cytochrome P450 (CYP) functional expression is reduced in uremia and normalized after restoration of kidney function via transplantation. The aim of this study was to evaluate the effect of conventional hemodialysis on the functional expression of CYP1A, 2C, and 3A. We also investigated the role of nuclear factor-κB (NF-κB) in CYP regulation during uremia. Primary cultures of normal rat hepatocytes were incubated with serum obtained from end-stage renal disease patients pre- and post-hemodialysis and healthy control subjects, in the presence and absence of the NF-κB inhibitor andrographolide. Uremic pre-hemodialysis serum caused significant reductions (P<0.01) in CYP1A (44%), 2C (27%), and 3A (35%) protein expression compared to control serum, while dialyzed serum (i.e., obtained immediately post-hemodialysis) had no effect. CYP1A2, 2C11, and 3A2 mRNA expression, as well as CYP3A activity, were similarly impacted by uremic serum and were improved to >80% of control values after hemodialysis. NF-κB inhibition nearly eliminated the effect of uremic serum on CYP functional expression. This is the first study to demonstrate that conventional hemodialysis acutely improves altered CYP functional expression observed in rat hepatocytes incubated with uremic human serum. Cytochrome P450 (CYP) functional expression is reduced in uremia and normalized after restoration of kidney function via transplantation. The aim of this study was to evaluate the effect of conventional hemodialysis on the functional expression of CYP1A, 2C, and 3A. We also investigated the role of nuclear factor-KB (NF-кB) in CYP regulation during uremia. Primary cultures of normal rat hepatocytes were incubated with serum obtained from end-stage renal disease patients pre- and post-hemodialysis and healthy control subjects, in the presence and absence of the NF-кB inhibitor andrographolide. Uremic pre-hemodialysis serum caused significant reductions (P<0.01) in CYP1A (44%), 2C (27%), and 3A (35%) protein expression compared to control serum, while dialyzed serum (i.e., obtained immediately post-hemodialysis) had no effect. CYP1A2, 2C11, and 3A2 mRNA expression, as well as CYP3A activity, were similarly impacted by uremic serum and were improved to >80% of control values after hemodialysis. NF-кB inhibition nearly eliminated the effect of uremic serum on CYP functional expression. This is the first study to demonstrate that conventional hemodialysis acutely improves altered CYP functional expression observed in rat hepatocytes incubated with uremic human serum. Cytochrome P450 (CYP) functional expression is reduced in uremia and normalized after restoration of kidney function via transplantation. The aim of this study was to evaluate the effect of conventional hemodialysis on the functional expression of CYP1A, 2C, and 3A. We also investigated the role of nuclear factor-κB (NF-κB) in CYP regulation during uremia. Primary cultures of normal rat hepatocytes were incubated with serum obtained from end-stage renal disease patients pre- and post-hemodialysis and healthy control subjects, in the presence and absence of the NF-κB inhibitor andrographolide. Uremic pre-hemodialysis serum caused significant reductions (P<0.01) in CYP1A (44%), 2C (27%), and 3A (35%) protein expression compared to control serum, while dialyzed serum (i.e., obtained immediately post-hemodialysis) had no effect. CYP1A2, 2C11, and 3A2 mRNA expression, as well as CYP3A activity, were similarly impacted by uremic serum and were improved to >80% of control values after hemodialysis. NF-κB inhibition nearly eliminated the effect of uremic serum on CYP functional expression. This is the first study to demonstrate that conventional hemodialysis acutely improves altered CYP functional expression observed in rat hepatocytes incubated with uremic human serum. Keywords:: hemodialysis, end-stage renal disease, cytochrome P450, gene expression, drug metabolism Cytochrome P450 (CYP) functional expression is reduced in uremia and normalized after restoration of kidney function via transplantation. The aim of this study was to evaluate the effect of conventional hemodialysis on the functional expression of CYP1A, 2C, and 3A. We also investigated the role of nuclear factor-kappaB (NF-kappaB) in CYP regulation during uremia. Primary cultures of normal rat hepatocytes were incubated with serum obtained from end-stage renal disease patients pre- and post-hemodialysis and healthy control subjects, in the presence and absence of the NF-kappaB inhibitor andrographolide. Uremic pre-hemodialysis serum caused significant reductions (P<0.01) in CYP1A (44%), 2C (27%), and 3A (35%) protein expression compared to control serum, while dialyzed serum (i.e., obtained immediately post-hemodialysis) had no effect. CYP1A2, 2C11, and 3A2 mRNA expression, as well as CYP3A activity, were similarly impacted by uremic serum and were improved to >80% of control values after hemodialysis. NF-kappaB inhibition nearly eliminated the effect of uremic serum on CYP functional expression. This is the first study to demonstrate that conventional hemodialysis acutely improves altered CYP functional expression observed in rat hepatocytes incubated with uremic human serum. Cytochrome P450 (CYP) functional expression is reduced in uremia and normalized after restoration of kidney function via transplantation. The aim of this study was to evaluate the effect of conventional hemodialysis on the functional expression of CYP1A, 2C, and 3A. We also investigated the role of nuclear factor-kappaB (NF-kappaB) in CYP regulation during uremia. Primary cultures of normal rat hepatocytes were incubated with serum obtained from end-stage renal disease patients pre- and post-hemodialysis and healthy control subjects, in the presence and absence of the NF-kappaB inhibitor andrographolide. Uremic pre-hemodialysis serum caused significant reductions (P<0.01) in CYP1A (44%), 2C (27%), and 3A (35%) protein expression compared to control serum, while dialyzed serum (i.e., obtained immediately post-hemodialysis) had no effect. CYP1A2, 2C11, and 3A2 mRNA expression, as well as CYP3A activity, were similarly impacted by uremic serum and were improved to >80% of control values after hemodialysis. NF-kappaB inhibition nearly eliminated the effect of uremic serum on CYP functional expression. This is the first study to demonstrate that conventional hemodialysis acutely improves altered CYP functional expression observed in rat hepatocytes incubated with uremic human serum.Cytochrome P450 (CYP) functional expression is reduced in uremia and normalized after restoration of kidney function via transplantation. The aim of this study was to evaluate the effect of conventional hemodialysis on the functional expression of CYP1A, 2C, and 3A. We also investigated the role of nuclear factor-kappaB (NF-kappaB) in CYP regulation during uremia. Primary cultures of normal rat hepatocytes were incubated with serum obtained from end-stage renal disease patients pre- and post-hemodialysis and healthy control subjects, in the presence and absence of the NF-kappaB inhibitor andrographolide. Uremic pre-hemodialysis serum caused significant reductions (P<0.01) in CYP1A (44%), 2C (27%), and 3A (35%) protein expression compared to control serum, while dialyzed serum (i.e., obtained immediately post-hemodialysis) had no effect. CYP1A2, 2C11, and 3A2 mRNA expression, as well as CYP3A activity, were similarly impacted by uremic serum and were improved to >80% of control values after hemodialysis. NF-kappaB inhibition nearly eliminated the effect of uremic serum on CYP functional expression. This is the first study to demonstrate that conventional hemodialysis acutely improves altered CYP functional expression observed in rat hepatocytes incubated with uremic human serum. |
Author | Nolin, Thomas D. Pichette, Vincent Michaud, Josée Lafrance, Jean-Philippe Dani, Mélina Himmelfarb, Jonathan Leblond, Francois A. Naud, Judith |
Author_xml | – sequence: 1 givenname: Josée surname: Michaud fullname: Michaud, Josée organization: Service de Néphrologie et Centre de Recherche Guy-Bernier, Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada H1T 2M4 – sequence: 2 givenname: Thomas D. surname: Nolin fullname: Nolin, Thomas D. organization: Division of Nephrology and Transplantation, Department of Medicine, Maine Medical Center, Portland, ME 04102, USA – sequence: 3 givenname: Judith surname: Naud fullname: Naud, Judith organization: Service de Néphrologie et Centre de Recherche Guy-Bernier, Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada H1T 2M4 – sequence: 4 givenname: Mélina surname: Dani fullname: Dani, Mélina organization: Service de Néphrologie et Centre de Recherche Guy-Bernier, Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada H1T 2M4 – sequence: 5 givenname: Jean-Philippe surname: Lafrance fullname: Lafrance, Jean-Philippe organization: Service de Néphrologie et Centre de Recherche Guy-Bernier, Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada H1T 2M4 – sequence: 6 givenname: Francois A. surname: Leblond fullname: Leblond, Francois A. organization: Division of Nephrology and Transplantation, Department of Medicine, Maine Medical Center, Portland, ME 04102, USA – sequence: 7 givenname: Jonathan surname: Himmelfarb fullname: Himmelfarb, Jonathan organization: Division of Nephrology and Transplantation, Department of Medicine, Maine Medical Center, Portland, ME 04102, USA – sequence: 8 givenname: Vincent surname: Pichette fullname: Pichette, Vincent email: vpichette.hmr@ssss.gouv.qc.ca organization: Service de Néphrologie et Centre de Recherche Guy-Bernier, Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada H1T 2M4 |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/18845914$$D View this record in MEDLINE/PubMed |
BookMark | eNptUj1v2zAQFYoUzUe7dS40dapTfomixsK1kwABmqGdiTN1jGnIoktKRf3ve7YcD0UGnUjp3XvH93hdXPSxx6L4yNktF5X6utmt8y0zTInl05viiktVz4xW5uK85vKyuM55w5gwjOt3xSU3RlUNV1fF3cJ7dEMZfXmP29gG6PY55DL2tN_BEFw53w_RrVPcYvmkKlYux94NIfbQlYu_u4Q50-Z98dZDl_HD6X1T_Foufs7vZ48_7h7m3x5nrpbVMEPNVV0jc1gL5wWIlZReQo24qoC3vKpdI41ohUdN4zrnPLbA_IpLD1rV8qZ4mHjbCBu7S2ELaW8jBHv8ENOzhURTd2hBttK0xCzIB62YQRRYAzeVkthWnrg-T1y7FH-PmAe7Ddlh10GPccxWN7ohcEPATyfguNpie5Z9sZEAYgK4FHNO6K0LAxxMGhKEznJmD1nZQ1b2lBU1ffmv6cz7OnwxwWmC4KCLfRd6tJs4JooiW-d1dgF7KxgzlnHqE5YdHnKVipZNUzWHw3yfeDZ5gGc8i77YdhSlbiuO9SR__u3WkCz2RKMnGqS0_wRM9qjuaLhEF4riCK-f4x9_9dbJ |
CitedBy_id | crossref_primary_10_1002_jps_22640 crossref_primary_10_1124_dmd_116_070052 crossref_primary_10_3390_toxins11040209 crossref_primary_10_1186_s40360_018_0221_6 crossref_primary_10_1002_jcph_2043 crossref_primary_10_1016_j_banm_2022_10_018 crossref_primary_10_1021_acs_molpharmaceut_9b00459 crossref_primary_10_1586_ecp_11_66 crossref_primary_10_1016_j_jpba_2020_113202 crossref_primary_10_1016_j_pharep_2018_12_007 crossref_primary_10_1111_1744_9987_12100 crossref_primary_10_1080_00498254_2021_1909783 crossref_primary_10_1093_ndt_gfad038 crossref_primary_10_3390_toxins5081475 crossref_primary_10_1002_cpt_1875 crossref_primary_10_1124_dmd_113_054171 crossref_primary_10_3851_IMP2941 crossref_primary_10_1177_0091270011415410 crossref_primary_10_36290_vnl_2020_057 crossref_primary_10_5604_01_3001_0012_7868 crossref_primary_10_1111_sdi_12484 crossref_primary_10_1007_s00228_009_0678_8 crossref_primary_10_1007_s40262_014_0146_1 crossref_primary_10_1517_17425255_2013_835802 crossref_primary_10_1038_clpt_2009_163 crossref_primary_10_1038_s41374_021_00610_9 crossref_primary_10_1248_yakushi_132_461 crossref_primary_10_1002_cpdd_238 crossref_primary_10_1053_j_ackd_2015_10_002 crossref_primary_10_1016_j_semnephrol_2014_02_010 crossref_primary_10_1002_jcph_349 crossref_primary_10_1016_j_semnephrol_2012_12_016 crossref_primary_10_3390_ijms252212279 crossref_primary_10_1096_fj_14_258780 crossref_primary_10_1053_j_ajkd_2014_09_015 crossref_primary_10_1177_0091270011413588 crossref_primary_10_1016_j_yrtph_2013_10_006 crossref_primary_10_1038_s41581_019_0111_1 crossref_primary_10_1053_j_ackd_2012_10_004 crossref_primary_10_3346_jkms_2018_33_e298 crossref_primary_10_1007_s11095_019_2593_8 crossref_primary_10_1002_jcph_1818 crossref_primary_10_1592_phco_29_5_562 crossref_primary_10_1038_ki_2012_193 crossref_primary_10_1093_ndt_gft091 crossref_primary_10_1111_bcp_12733 crossref_primary_10_1038_ki_2013_399 crossref_primary_10_1093_toxsci_kfw193 crossref_primary_10_1186_s41100_016_0091_6 crossref_primary_10_1016_j_crphar_2021_100020 crossref_primary_10_1194_jlr_P040022 crossref_primary_10_1016_j_nephro_2014_12_006 crossref_primary_10_2165_11593320_000000000_00000 |
Cites_doi | 10.1016/j.pharmthera.2005.05.010 10.1038/sj.bjp.0704951 10.1248/bpb.25.1077 10.1038/sj.clpt.1996.43 10.1124/dmd.104.000521 10.1038/sj.bjp.0706138 10.1016/j.ajkd.2003.07.019 10.1038/clpt.1993.198 10.1016/j.vascn.2006.07.002 10.1016/S0009-9236(03)00056-0 10.1681/ASN.V122326 10.1681/ASN.2006060610 10.1681/ASN.2006010035 10.1074/jbc.M106286200 10.1124/dmd.107.018192 10.1074/jbc.M111013200 10.1023/A:1016044032571 10.1016/S0090-9556(24)15079-9 10.1016/S0022-3565(25)21242-3 10.1016/S0009-9236(03)00015-8 |
ContentType | Journal Article |
Copyright | 2008 Elsevier B.V. The Japanese Pharmacological Society 2008 |
Copyright_xml | – notice: 2008 Elsevier B.V. – notice: The Japanese Pharmacological Society 2008 |
CorporateAuthor | Division of Nephrology and Transplantation Scarborough Maine Medical Center Research Institute Service de Nephrologie et Centre de Recherche Guy-Bernier Hopital Maisonneuve-Rosemont Department of Medicine Center for Clinical and Translational Research Maine Medical Center Departeinent de Pharmacologie Universite de Montreal |
CorporateAuthor_xml | – name: Maine Medical Center Research Institute – name: Scarborough – name: Division of Nephrology and Transplantation – name: Service de Nephrologie et Centre de Recherche Guy-Bernier – name: Department of Medicine – name: Hopital Maisonneuve-Rosemont – name: Maine Medical Center – name: Departeinent de Pharmacologie – name: Universite de Montreal – name: Center for Clinical and Translational Research |
DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 DOA |
DOI | 10.1254/jphs.08042FP |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1347-8648 |
EndPage | 163 |
ExternalDocumentID | oai_doaj_org_article_a3d38deeb21346408ee2e7a18543ed5f 18845914 10_1254_jphs_08042FP cf6scien_2008_010802_002_0157_016399599 article_jphs_108_2_108_08042FP_article_char_en S1347861319313507 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- .55 .GJ 0R~ 0SF 29L 2WC 3O- 4.4 457 53G 5GY 5RE 6I. AACTN AAEDT AAEDW AAFTH AAIKJ AALRI AAXUO ABMAC ACGFO ACGFS ADBBV ADEZE AENEX AEXQZ AFTJW AGHFR AHPSJ AITUG AL- ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BCNDV BKOMP CS3 DIK DU5 E3Z EBS EJD F5P FDB GROUPED_DOAJ GX1 HH5 IPNFZ JMI JSF JSH KQ8 M41 MOJWN M~E NCXOZ O9- OK1 RIG RJT RNS ROL RZJ SSZ TKC TR2 W2D X7M XSB ZGI ZXP AAYWO ACVFH ADCNI ADVLN AEUPX AFJKZ AFPUW AIGII AKBMS AKRWK AKYEP APXCP OVT AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c735t-e61477e0ce72cf2a2b33f3a7eeb5a1d157c9382d2fe6002cccfeda0fb13fa6473 |
IEDL.DBID | DOA |
ISSN | 1347-8613 |
IngestDate | Mon Sep 08 19:52:56 EDT 2025 Fri Jul 11 12:01:08 EDT 2025 Sat Sep 28 08:36:10 EDT 2024 Tue Jul 01 01:26:56 EDT 2025 Thu Apr 24 22:52:10 EDT 2025 Thu Jul 10 16:10:40 EDT 2025 Wed Sep 03 06:30:16 EDT 2025 Fri Feb 23 02:27:12 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | hemodialysis cytochrome P450 end-stage renal disease gene expression drug metabolism |
Language | English |
License | http://creativecommons.org/licenses/by-nc-nd/4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c735t-e61477e0ce72cf2a2b33f3a7eeb5a1d157c9382d2fe6002cccfeda0fb13fa6473 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://doaj.org/article/a3d38deeb21346408ee2e7a18543ed5f |
PMID | 18845914 |
PQID | 69698549 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_a3d38deeb21346408ee2e7a18543ed5f proquest_miscellaneous_69698549 pubmed_primary_18845914 crossref_citationtrail_10_1254_jphs_08042FP crossref_primary_10_1254_jphs_08042FP medicalonline_journals_cf6scien_2008_010802_002_0157_016399599 jstage_primary_article_jphs_108_2_108_08042FP_article_char_en elsevier_sciencedirect_doi_10_1254_jphs_08042FP |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2008-00-00 |
PublicationDateYYYYMMDD | 2008-01-01 |
PublicationDate_xml | – year: 2008 text: 2008-00-00 |
PublicationDecade | 2000 |
PublicationPlace | Japan |
PublicationPlace_xml | – name: Japan |
PublicationTitle | Journal of Pharmacological Sciences |
PublicationTitleAlternate | J Pharmacol Sci |
PublicationYear | 2008 |
Publisher | Elsevier B.V The Japanese Pharmacological Society Elsevier |
Publisher_xml | – name: Elsevier B.V – name: The Japanese Pharmacological Society – name: Elsevier |
References | 4 Nolin TD, Frye RF, Matzke GR. Hepatic drug metabolism and transport in patients with kidney disease. Am J Kidney Dis. 2003;42:906–925. 12 Nolin TD, Appiah K, Kendrick SA, Le P, McMonagle E, Himmelfarb J. Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J Am Soc Nephrol. 2006;17:2363–2367. 19 Taburet AM, Vincent I, Perello L, Coret B, Baune B, Furlan V. Impairment of drug biotransformation in renal disease an in vitro model. Clin Pharmacol Ther. 1996;59:136. 9 Dreisbach AW, Japa S, Gebrekal AB, Mowry SE, Lertora JJ, Kamath BL, et al. Cytochrome P4502C9 activity in end-stage renal disease. Clin Pharmacol Ther. 2003;73:475–477. 1 Michaud J, Dubé P, Naud J, Leblond FA, Desbiens K, Bonnardeaux A, et al. Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br J Pharmacol. 2005;144:1067–1077. 13 Michaud J, Naud J, Chouinard J, Desy F, Leblond FA, Desbiens K. Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure. J Am Soc Nephrol. 2006;17:3041–3048. 10 Dowling TC, Briglia AE, Fink JC, Hanes DS, Light PD, Stackiewicz L, et al. Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease. Clin Pharmacol Ther. 2003;73:427–434. 16 Guillen C, Martinez P, de Gortazar AR, Martinez ME, Esbrit P. Both N- and C-terminal domains of parathyroid hormone-related protein increase interleukin-6 by nuclear factor-kappa B activation in osteoblastic cells. J Biol Chem. 2002;277:28109–28117. 18 Yoshitani T, Yagi H, Inotsume N, Yasuhara M. Effect of experimental renal failure on the pharmacokinetics of losartan in rats. Biol Pharm Bull. 2002;25:1077–1083. 6 Leblond F, Guevin C, Demers C, Pellerin I, Gascon-Barre M, Pichette V. Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol. 2001;12:326–332. 14 Ke S, Rabson AB, Germino JF, Gallo MA, Tian Y. Mechanism of suppression of cytochrome P-450 1A1 expression by tumor necrosis factor-alpha and lipopolysaccharide. J Biol Chem. 2001;276:39638–39644. 20 Yamazaki M, Akiyama S, Nishigaki R, Sugiyama Y. Uptake is the rate-limiting step in the overall hepatic elimination of pravastatin at steady-state in rats. Pharm Res. 1996;13:1559–1564. 8 Sun H, Huang Y, Frassetto L, Benet LZ. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Dispos. 2004;32:1239–1246. 7 Guevin C, Michaud J, Naud J, Leblond FA, Pichette V. Down-regulation of hepatic cytochrome P450 in chronic renal failure: role of uremic mediators. Br J Pharmacol. 2002;137:1039–1046. 2 Naud J, Michaud J, Leblond FA, Lefrancois S, Bonnardeaux A, Pichette V. Effects of chronic renal failure on liver drug transporters. Drug Metab Dispos. 2008;36:124–128. 5 Leblond FA, Giroux L, Villeneuve JP, Pichette V. Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Dispos. 2000;28:1317–1320. 11 Kim YG, Shin JG, Shin SG, Jang IJ, Kim S, Lee JS, et al. Decreased acetylation of isoniazid in chronic renal failure. Clin Pharmacol Ther. 1993;54:612–620. 3 Sun H, Frassetto L, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol Ther. 2006;109:1–11. 17 Terao N, Shen DD. Reduced extraction of I-propranolol by perfused rat liver in the presence of uremic blood. J Pharmacol Exp Ther. 1985;233:277–284. 15 Michaud J, Leblond FA, Naud J, Boisvert C, Desbiens K, Nicoll-Griffith DA, et al. Use of a fluorescent substrate for the selective quantification of rat CYP3A in the liver and the intestine. J Pharmacol Toxicol Methods. 2007;55:209–213. 12 13 14 15 16 18 19 LEBLOND F A (5) 2000; 28 1 2 3 4 6 7 8 9 Terao N., Shen D. D. (17) 1985; 233 (11) 1993; 54 20 10 |
References_xml | – reference: 13 Michaud J, Naud J, Chouinard J, Desy F, Leblond FA, Desbiens K. Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure. J Am Soc Nephrol. 2006;17:3041–3048. – reference: 11 Kim YG, Shin JG, Shin SG, Jang IJ, Kim S, Lee JS, et al. Decreased acetylation of isoniazid in chronic renal failure. Clin Pharmacol Ther. 1993;54:612–620. – reference: 19 Taburet AM, Vincent I, Perello L, Coret B, Baune B, Furlan V. Impairment of drug biotransformation in renal disease an in vitro model. Clin Pharmacol Ther. 1996;59:136. – reference: 6 Leblond F, Guevin C, Demers C, Pellerin I, Gascon-Barre M, Pichette V. Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol. 2001;12:326–332. – reference: 9 Dreisbach AW, Japa S, Gebrekal AB, Mowry SE, Lertora JJ, Kamath BL, et al. Cytochrome P4502C9 activity in end-stage renal disease. Clin Pharmacol Ther. 2003;73:475–477. – reference: 14 Ke S, Rabson AB, Germino JF, Gallo MA, Tian Y. Mechanism of suppression of cytochrome P-450 1A1 expression by tumor necrosis factor-alpha and lipopolysaccharide. J Biol Chem. 2001;276:39638–39644. – reference: 17 Terao N, Shen DD. Reduced extraction of I-propranolol by perfused rat liver in the presence of uremic blood. J Pharmacol Exp Ther. 1985;233:277–284. – reference: 12 Nolin TD, Appiah K, Kendrick SA, Le P, McMonagle E, Himmelfarb J. Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J Am Soc Nephrol. 2006;17:2363–2367. – reference: 18 Yoshitani T, Yagi H, Inotsume N, Yasuhara M. Effect of experimental renal failure on the pharmacokinetics of losartan in rats. Biol Pharm Bull. 2002;25:1077–1083. – reference: 3 Sun H, Frassetto L, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol Ther. 2006;109:1–11. – reference: 5 Leblond FA, Giroux L, Villeneuve JP, Pichette V. Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Dispos. 2000;28:1317–1320. – reference: 20 Yamazaki M, Akiyama S, Nishigaki R, Sugiyama Y. Uptake is the rate-limiting step in the overall hepatic elimination of pravastatin at steady-state in rats. Pharm Res. 1996;13:1559–1564. – reference: 10 Dowling TC, Briglia AE, Fink JC, Hanes DS, Light PD, Stackiewicz L, et al. Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease. Clin Pharmacol Ther. 2003;73:427–434. – reference: 15 Michaud J, Leblond FA, Naud J, Boisvert C, Desbiens K, Nicoll-Griffith DA, et al. Use of a fluorescent substrate for the selective quantification of rat CYP3A in the liver and the intestine. J Pharmacol Toxicol Methods. 2007;55:209–213. – reference: 1 Michaud J, Dubé P, Naud J, Leblond FA, Desbiens K, Bonnardeaux A, et al. Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br J Pharmacol. 2005;144:1067–1077. – reference: 2 Naud J, Michaud J, Leblond FA, Lefrancois S, Bonnardeaux A, Pichette V. Effects of chronic renal failure on liver drug transporters. Drug Metab Dispos. 2008;36:124–128. – reference: 7 Guevin C, Michaud J, Naud J, Leblond FA, Pichette V. Down-regulation of hepatic cytochrome P450 in chronic renal failure: role of uremic mediators. Br J Pharmacol. 2002;137:1039–1046. – reference: 16 Guillen C, Martinez P, de Gortazar AR, Martinez ME, Esbrit P. Both N- and C-terminal domains of parathyroid hormone-related protein increase interleukin-6 by nuclear factor-kappa B activation in osteoblastic cells. J Biol Chem. 2002;277:28109–28117. – reference: 4 Nolin TD, Frye RF, Matzke GR. Hepatic drug metabolism and transport in patients with kidney disease. Am J Kidney Dis. 2003;42:906–925. – reference: 8 Sun H, Huang Y, Frassetto L, Benet LZ. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Dispos. 2004;32:1239–1246. – ident: 3 doi: 10.1016/j.pharmthera.2005.05.010 – ident: 7 doi: 10.1038/sj.bjp.0704951 – ident: 18 doi: 10.1248/bpb.25.1077 – ident: 19 doi: 10.1038/sj.clpt.1996.43 – ident: 8 doi: 10.1124/dmd.104.000521 – ident: 1 doi: 10.1038/sj.bjp.0706138 – ident: 4 doi: 10.1016/j.ajkd.2003.07.019 – volume: 54 start-page: 612 issn: 0009-9236 issue: 6 year: 1993 ident: 11 doi: 10.1038/clpt.1993.198 – ident: 15 doi: 10.1016/j.vascn.2006.07.002 – ident: 10 doi: 10.1016/S0009-9236(03)00056-0 – ident: 6 doi: 10.1681/ASN.V122326 – ident: 12 doi: 10.1681/ASN.2006060610 – ident: 13 doi: 10.1681/ASN.2006010035 – ident: 14 doi: 10.1074/jbc.M106286200 – ident: 2 doi: 10.1124/dmd.107.018192 – ident: 16 doi: 10.1074/jbc.M111013200 – ident: 20 doi: 10.1023/A:1016044032571 – volume: 28 start-page: 1317 issn: 0090-9556 issue: 11 year: 2000 ident: 5 doi: 10.1016/S0090-9556(24)15079-9 – volume: 233 start-page: 277 issn: 0022-3565 issue: 2 year: 1985 ident: 17 doi: 10.1016/S0022-3565(25)21242-3 – ident: 9 doi: 10.1016/S0009-9236(03)00015-8 |
SSID | ssj0028016 ssib002822155 ssib044745378 ssib058493307 |
Score | 2.0844877 |
Snippet | Cytochrome P450 (CYP) functional expression is reduced in uremia and normalized after restoration of kidney function via transplantation. The aim of this study... |
SourceID | doaj proquest pubmed crossref medicalonline jstage elsevier |
SourceType | Open Website Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 157 |
SubjectTerms | Aged Aged, 80 and over Animals Aryl Hydrocarbon Hydroxylases - metabolism Cells, Cultured Cytochrome P-450 CYP1A2 - metabolism Cytochrome P-450 CYP3A Cytochrome P-450 Enzyme System - genetics Cytochrome P-450 Enzyme System - metabolism cytochrome P450 Cytochrome P450 Family 2 Cytochromes Diterpenes - pharmacology Down-Regulation drug metabolism end-stage renal disease Female gene expression Gene Expression Regulation, Enzymologic hemodialysis Hepatocytes - drug effects Hepatocytes - enzymology Humans Kidney Failure, Chronic - blood Kidney Failure, Chronic - therapy Liver - drug effects Liver - enzymology Male Membrane Proteins - metabolism Middle Aged NF-kappa B - antagonists & inhibitors NF-kappa B - metabolism Rats Rats, Sprague-Dawley Renal Dialysis RNA, Messenger - metabolism Steroid 16-alpha-Hydroxylase - metabolism Uremia - blood Uremia - therapy |
Title | Effect of Hemodialysis on Hepatic Cytochrome P450 Functional Expression |
URI | https://dx.doi.org/10.1254/jphs.08042FP https://www.jstage.jst.go.jp/article/jphs/108/2/108_08042FP/_article/-char/en http://mol.medicalonline.jp/en/journal/download?GoodsID=cf6scien/2008/010802/002&name=0157-0163e https://www.ncbi.nlm.nih.gov/pubmed/18845914 https://www.proquest.com/docview/69698549 https://doaj.org/article/a3d38deeb21346408ee2e7a18543ed5f |
Volume | 108 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Journal of Pharmacological Sciences, 2008, Vol.108(2), pp.157-163 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Nb9MwFLfQTkgI8U1hDB9gFxbq2E4cH0CCqaVCGuphk3azHMfWNrFkWjuJXvjbeS92WnqouHCopTZPcfPey_uw3_uZkHe1x1PfKlxesiyTPDSZLmuZKYkBMAuFdtjgfPKjnJ3J7-fF-V9HfWFNWIQHjowbW9GIqvGQAOZClpJV3nOvLLgZKXxTBLS-TLMhmUqpFtjdvq9ISLDB4LFSyTtkQ-Orm4vFR4iTJJ_Ot5xRj9m_7ZOuIELD1vsH13HXJKJX7A5Ge6c0fUQepmiSfolP8Zjc8-0TcjiPcNSrI3q66a5aHNFDOt8AVa-ekm8Ruph2gc78dYctJIhPQrsWvmOltaPHq2XnLhDSgM5lwegU3GBcPaSTX6mGtn1GzqaT0-NZlg5WyJwSxTLz4JOV8sx5xV3gltdCBGEVcLmweZMXymlR8YYHj9t2zrngG8tCnYtgS6nEc7LXdq1_SSgva-aE55WruYTYyFaqDrV2VnG4tWYj8mHgsHEJdRwPv_hpMPsAeRiUh0nyGJH3a-qbiLaxg-4rCmtNgxjZ_Q-gOSZpjvmX5ozIeBC1SeFGDCPgVpc7pv0UNWI98TBXT5WzyvB-TPTry9hBB2ZoRD5vKZJJ9mJhXCj7v5BOBcXCT24YfkAYMGAcWWg9Im8HzTNgBnBvx7a-u1uYUpcaHgwoXkSF3PCvqmShc_nqf_DsNbkfC2ZwDWqf7C1v7_wbiMqW9UH_Ah6gZyxgPPk9-QMueDYj |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+Hemodialysis+on+Hepatic+Cytochrome+P450+Functional+Expression&rft.jtitle=Journal+of+pharmacological+sciences&rft.au=Jos%C3%A9e+Michaud&rft.au=Thomas+D.+Nolin&rft.au=Judith+Naud&rft.au=M%C3%A9lina+Dani&rft.date=2008&rft.pub=Elsevier&rft.issn=1347-8613&rft.volume=108&rft.issue=2&rft.spage=157&rft.epage=163&rft_id=info:doi/10.1254%2Fjphs.08042FP&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_a3d38deeb21346408ee2e7a18543ed5f |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1347-8613&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1347-8613&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1347-8613&client=summon |